WASHINGTON STATE CONVENTION CENTER

Seattle, Washington
March 4–7, 2019

 

Conference Dates and Location: 
March 4–7, 2019 | Seattle, Washington
Abstract Number: 
560

A REAL-WORLD STUDY OF EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN HCV PATIENTS

Author(s): 

Marcello Persico1, Andrea Aglitti1, Michele Milella2, Carmine Coppola3, Vincenzo Messina4, Ernesto Claar5, Ivan Gentile6, Paola Pierri7, Lorenzo Antonio Surace8, Filomena Morisco6, Paolo Tundo9, Giuseppina Brancaccio10, Nicola Coppola10, Annamaria Longo11, Mario Masarone1

1University of Salerno, Salerno, Italy,2University of Bari, Bari, Italy,3ASL Naples, Naples, Italy,4Azienda Ospedaliera Sant'Anna e San Sebastiano di Caserta, Caserta, Italy,5Evangelical Hospital Villa Betania Naples, Naples, Italy,6University of Naples Federico II, Naples, Italy,7AORN dei Colli, Naples, Italy,8Centro Medicina del Viaggiatore e delle Migrazioni, Lamezia Terme, Italy,9Hospital Santa Caterina Novella, Galatina, Italy,10Second University of Naples, Caserta, Italy,11Perrino Hospital, Brindisi, Italy

Abstract Body: 

Data on the effectiveness and safety of Glecaprevir/Pibrentasvir for the treatment of HCV infection in a 'field-practice' scenario are still scant. This study (MISTRAL: MavIret SouTh italy ReAl Life), currently ongoing, evaluates this therapy in a large cohort of HCV-infected patients from Southern Italy.

All HCV-infected patients, consecutively treated with Glecaprevir/Pibrentasvir at 22 Centers all over Southern Italy were considered. Fibrosis was determined histologically or non-invasively, through liver stiffness measurement. We report here baseline characteristics of patients and available data on end of treatment (EOT). Efficacy of treatment was defined as undetectable HCV-RNA in patients' blood sample obtained twelve weeks after the end of therapy (sustained virological response).

In total, 1178 patients were enrolled (mean age, 60±15 years; 581 males, 49.4%). Most common etiologies were HCV 1b (n=432; 36.8%) and HCV 2 (n=405; 34.5%). One hundred and twenty-three patients (10.5%) were infected from genotype-3 HCV. METAVIR score was F0 in 269 patients (22.9%), F1 in 477 (40.6%), F2 in 209 (17.8%), F3 in 92 (7.8%) and F4 in 103 (8.8%). The wide majority of patients showed normal (CKD1; n=572, 48.7%) or mildly impaired (CKD2; n=472, 40.2%) renal function; 28 subjects had kidney failure (CKD5; 2.4%). Ninety patients (7.7%) were diabetics. Laboratory parameters were as follows: creatinine, 1.02±1.17 mg/dl; bilirubin, 0.76±0.44 mg/dl; hemoglobin, 14.2±1.6 g/dl; platelets, 206874±64111/µl; ALT 45±38 U/L and AST 55±56 U/L. Most patients (n=918; 78.1%) were treatment-naïve. Planned duration of Glecaprevir/Pibrentasvir treatment was 8 weeks for 1067 patients (90.8%), 12 weeks for 102 (8.7%) and 16 weeks for 5 (0.4%). At the time of analysis, data concerning EOT were available for 1178 patients 100% of the total). Almost all of them reached EOT (99.5%). Data on sustained virological response at 12 weeks after EOT are not complete at the time of the present analysis we then here reported data on 885 patients showing a prevalence of 99.3% of SVR. SAE, not related to the drug, were documented in 1% of patients and 8.5% of AE (mostly pruritus).

The large MISTRAL study, conducted in a field-practice scenario, provides a still better prevalence, compared to registration trial, of SVR confirming the extraordinary efficacy and safety of Glecaprevir/Pibrentasvir association also for only 8 weeks treatment. Complete final results will be presented at the CROI meeting.

Session Number: 
P-K1
Session Title: 
HCV THERAPEUTICS: REALITY TESTING
Presenting Author: 
Marcello Persico
Presenter Institution: 
University of Salerno
Poster: